Dr. Matthew Seftel
Dr. Irfan Dhalla
Dr. Hakique Virani
Scott Klarenbach, MD, Professor and Clinician Scientist in the Department of Medicine at the University of Alberta
Tom Noseworthy, MD
Timothy Caulfield, LLM, FRSC, FCAHS
On December 8, Dr. Michael Burgess presented the last Canada's Drug Agency Lecture of 2015. Dr. Burgess argued that, taking into account the advantages and disadvantages of deliberative public engagement, it is best used when the scale and urgency of policy decisions justify the expense and effort.
On November 26, 2015, Dr. Renaldo Battista, Scientific Director, Fonds de recherche du Québec — Santé, and recipient of the Canada's Drug Agency Anniversary Medal and the Dr. Jill M. Sanders Award of Excellence in Health Technology Assessment, covered the evolution of HTA and discussed current and future opportunities in the field.
On October 27, 2015, Dr. Fiona Clement challenged some commonly held preconceptions about the Canadian health care system and put forward her ideas about what we could do differently. Dr. Clement proposed concrete steps forward for integrating evidence into the system and talked about what needs to change to get us to where she thinks we need to be — a sustainable, universally accessible, equitable health care system.
On September 24, 2015, Dr. Art Sedrakyan hosted an insightful lecture that demonstrated how the use of international data resources and routinely available US data can support informed decisions about hospital procedures and interventions and encourage national investment in device/intervention evaluations.
On June 9, 2015, Dr. Wendy Levinson provided an overview of Choosing Wisely Canada (CSC), described the ‘epidemic of overuse’, and discussed implementation efforts of Choosing Wisely recommendations within the Canadian health care environment by various health care organizations.
On May 25, 2015, Jon Brassey, Director, Trip Database, delivered a thought-provoking presentation focusing on the problems of systematic reviews, the rise of the rapid review, and the potential role of automation.
Sarah Berglas, Patient Engagement Officer, Canada's Drug Agency
Dr Marc Rhainds, Medical and Scientific Coordinator, Health Technology Assessment Unit, CHU de Québec
Susan Bazylewski, Vice-President, Care Services, and Louise Frederick, Patient Family Advisory Committee, Saskatchewan Cancer Agency
On March 12, 2015, Dr. Murray Krahn talked about developing a fair, transparent, and values-based framework for decisions about the adoption and use of health technologies.
On February 10, 2015, Dr. Jeffrey Hoch recognized some of the academic contributions of the late Professor Bernie O'Brien and how they are still relevant to HTA today.Last Updated : February 28, 2018
Canada's Drug Agency Lecture — Cost-Effectiveness of Naloxone Kits in Canadian High Schools and Community Centre SettingsEvent Date: March 5, 2020 The opioid crisis continues to devastate families and communities across Canada. According to the Public Health Agency of Canada, an estimated 12,800 Canadians died from an apparent opioid-related overdose between January 2016 and March 2019. This is a complex issue that requires a compassionate, multi-faceted, evidence-based response. One of those facets is health economics, the branch of economics concerned with how to best allocate scarce health care resources for maximum benefit. In this lecture, the role and impact of health economics in supporting decision-making will be explored using the case study of the cost-effectiveness of naloxone kits in Canadian high schools and community centre settings. |
|
Why Organizations, Researchers, and Patients Are Falling Prey to Predatory JournalsDr. Kelly Cobey Date: October 10, 2019 |
|
Why Oncology Needs More Common Sense and Less Cheerleading — A Case for a Centre for Sense in OncologyBishal Gyawali, MD, PhD Date: September 5, 2019 |
|
Gene Therapy: A Scientific Renaissance?
Date: Tuesday, February 27, 2018 |
|
HTA and Quality Improvement: The Whole is More than the Sum of Its Parts
Date: Wednesday, November 29, 2017 |
|
Canada’s Opioid Crisis: The Changing Reality Between Exam Rooms and Ivory Towers
Date: Thursday, October 12, 2017 |
|
An Introduction to Health Economics
Date: Monday, November 28, 2016, in person or via webinar |
|
The Emergence of Health Technology Optimization & Managed Exit
Date: Thursday, October 27, 2016 |
|
Panel Discussion on Making Evidence Meaningful: Optimal Use and Adoption of Medical Imaging EquipmentFrom Canada's Drug Agency Symposium 2016 Evidence indicates that 10% to 20% of medical imaging is unnecessary or inappropriate, which strains health resources, overburdens wait-lists and, in the case of computed tomography (CT) scans, exposes patients to unnecessary radiation doses. This session will explore the role that evidence-based advice, recommendations, and tools play in facilitating the appropriate use and adoption of medical imaging equipment. Canadian experts will identify meaningful evidence-based products and services that will support the appropriate use of new and existing imaging equipment. Panellists will also discuss methods to support the translation of this evidence into care. The session will briefly cover the Canada's Drug Agency work on the Canadian Medical Imaging Inventory. Panellists:
Moderator:
|
|
Oral Presentations on Patient and Public EngagementFrom Canada's Drug Agency Symposium 2016 Going Beyond Surveys: Bringing the Power of Patient Narrative to Patient Submissions
Patient Values
Integrating Qualitative Research Into Health Technology Assessment in Canada: The Canada's Drug Agency Experience
Using Qualitative Research Methods to Solicit Patient Experiences and Values for Health Technology Policy-Making: The Case of Non-Invasive Prenatal Testing
|
|
A “Revolution”? — The Limits of Personalized Medicine
Date: Tuesday, January 26, 2016 |
|
Is Deliberative Public Engagement Worth the Trouble?
Michael M. Burgess, PhD |
|
Health Technology Assessment: Then, Now, and Beyond…
Renaldo Battista, MD, MPH, ScD, FRCP (C) |
|
Imagining the Impossible: Redefining Canadian Health Care
Dr. Fiona Clement |
|
Comparative Effectiveness for Interventions and Devices
Art Sedrakyan, MD, PhD |
|
Choosing Wisely Canada: Evidence-Based Medicine and Changing the Canadian Health Care Environment
Dr. Wendy Levinson |
|
All That Glitters Is Not Gold — Are Systematic Reviews Fool's Gold?
Jon Brassey |
|
Patient Engagement in Health Technology AssessmentApril 13, 2015 at the 2015 Canada's Drug Agency Symposium in Saskatoon, Saskatchewan, conference members discussed different aspects of Patient Engagement and the processes of evaluating health technologies.
|
|
Developing a Values-Based Framework for Decision-Making in Technology Assessment (and Health)
Dr. Murray Krahn |
|
Judging the Gift From the Box: Reflections on the Power and Significance of Bernie O'Brien's "Power and Significance"
Dr. Jeffrey Hoch |
|
Last Updated : February 28, 2018